Retrospective Evaluation of Safety and Effectiveness of the EXOSEAL Vascular Closure Device for Single Vascular Closure and Closure after Repeat Puncture in Diagnostic and Interventional Radiology: Single-center Experience
“…This has already been shown for retrograde arterial access closures. 8 There are some limitations to the present study. Available data were analyzed retrospectively.…”
Section: Discussionmentioning
confidence: 86%
“…In general the safety and efficacy of these VCDs has been confirmed for retrograde access in several studies 11e13 even in patients receiving anticoagulant therapy 14,15 or after repeated closures. 8,16 Despite a steeper puncture angle, VCDs are also increasingly used for the closure of antegrade femoral access sites. 4,5 Studies examining the safety and efficacy of antegrade vascular closure devices demonstrated effectiveness in obtaining hemostasis.…”
ExoSeal vascular closure of antegrade femoral punctures is safe and effective with a low complication rate. Two minutes of MC are sufficient to achieve hemostasis in the majority of cases. However, in patients on antiplatelet therapy, especially after abciximab, the authors advocate prolonging MC to 5 minutes.
“…This has already been shown for retrograde arterial access closures. 8 There are some limitations to the present study. Available data were analyzed retrospectively.…”
Section: Discussionmentioning
confidence: 86%
“…In general the safety and efficacy of these VCDs has been confirmed for retrograde access in several studies 11e13 even in patients receiving anticoagulant therapy 14,15 or after repeated closures. 8,16 Despite a steeper puncture angle, VCDs are also increasingly used for the closure of antegrade femoral access sites. 4,5 Studies examining the safety and efficacy of antegrade vascular closure devices demonstrated effectiveness in obtaining hemostasis.…”
ExoSeal vascular closure of antegrade femoral punctures is safe and effective with a low complication rate. Two minutes of MC are sufficient to achieve hemostasis in the majority of cases. However, in patients on antiplatelet therapy, especially after abciximab, the authors advocate prolonging MC to 5 minutes.
“…The first study published on Exoseal 7 F included 60 patients and concluded Exoseal to be safe in size 7 F. Furthermore, a short time to hemostasis, short time to ambulation and low complication rates were observed (24). In another, recently published retrospective study on Exoseal 5 F, 6 F and 7 F, the device was assessed as safe and effective independently of its size or whether an intervention had previously taken place at the puncture site; however, the study was conducted exclusively on retrograde vascular interventions (25).…”
“…In a retrospective analysis, Boschewitz and coworkers reported the safety and effectiveness of the Exo-Seal system citing a very low complication rate of 1.17 % [36].…”
In the present study, there were no significant differences found regarding the occurrence of hematoma > 5 cm, major bleeding, false aneurysm, and device failure between Angio-Seal(®) and Exo-Seal(®) 24 h after device implantation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.